A board governance framework for evaluating CMC, Manufacturing & Quality (CMCQ) leadership in biopharma. Eight years to write, drawing on 120+ commercial product launches — the collective careers of sixteen CTOs who have led CMCQ at world-leading Fortune 100, mid-cap, and startup biotech. It replaces the question "is the CTO good?" with the more precise one: "is our CMC leadership calibrated to the risk most likely to end our next capital event?"
246 senior CMC, Quality, and technical leaders downloaded the framework in its first month — from large-cap pharma to clinical-stage biotech.
A representative sample of organizations whose teams downloaded the framework. We never share individual details.
Technical risk in biopharma rarely announces itself early. It is repriced later — by the FDA, an acquirer, the IPO market, or the next financing round. This framework helps boards identify and govern that risk before the capital event does.
Across 9,704 drug development programs, the probability of reaching approval from Phase I is roughly 6.7%. As clinical probabilities tighten, operational execution becomes a larger determinant of enterprise value — and boards systematically misprice it.
The most commonly cited approval-blocking deficiencies are not clinical. They are manufacturing and CMC. The FDA's July 2025 release of 202 Complete Response Letters confirmed that 74% cited quality or manufacturing deficiencies — up from roughly 15% two decades earlier.
A preventable manufacturing CRL has triggered single-day valuation declines in the 33–34% range. The difference from a clinical failure is decisive: manufacturing CRLs sit within the CTO's mandate. They are preventable with the right governance.
CMC performance is not fixed "technical strength." It is a stage-specific risk function with five simultaneous dimensions. At any given stage, one mandate is dominant — its failure is most likely to be fatal to the current capital event — but the others remain active. The correct mental model is a radar chart, not a checklist.
Make a product possible. Translation into an investable, regulator-legible development position.
Make it reproducible. Systems replace heroics. CMC, assay, and process control are institutionalized.
Make it diligence-survivable. Documentation integrity, auditability, and narrative stability under scrutiny.
Build the operational machine. The platform becomes a multi-program operating system.
Harden enterprise performance under stress. Inspections, shortages, geopolitics, redundancy.
These weightings are directional, not predictive. The value lies in the conversation they structure. The full framework maps dominant, rising, and maintenance mandates across all five stages, with a board calibration tool that surfaces where directors disagree about what the role requires.
Manufacturing CRLs triggered 33–34% single-day declines. Clinical failures triggered 50–75%. The difference: manufacturing CRLs sit within the CTO's mandate. They are preventable with the right governance.
| Company | Year | Valuation impact | CRL type |
|---|---|---|---|
| Fortress Biotech | 2025 | −33.7% | CMC / Mfg |
| Alvotech | 2025–26 | −34% | CMC / Mfg |
| Immunomedics | 2019–20 | Delayed | CMC / Mfg |
| Applied Therapeutics | 2024 | −75% | Clinical |
| Corcept Therapeutics | 2025 | −50% | Clinical |
Three roles boards routinely conflate. They own different risks — and each is the priority hire at a different moment.
| Role | What they own | The risk they retire | Priority hire when… |
|---|---|---|---|
| Chief Technology Officer (CTO) | Whole CMC and technical strategy across the lifecycle | The therapy cannot be made, scaled, or defended to a regulator | Series B+ scale-up, pre-IPO calibration, or M&A readiness |
| Head of Technical Operations | Day-to-day manufacturing, tech transfer, and supply | A process that will not reproduce at commercial volume | Moving from clinical to commercial supply |
| VP Quality / CQO | Quality systems, compliance, and inspection readiness | A quality system that buckles at inspection or at scale | Pre-approval inspection, or after a quality signal |
A voting director with hands-on CMC operating experience — not a scientific advisor. A fiduciary who has managed CAPA systems, led pre-approval inspections, and negotiated CMC deficiency responses with the FDA, and who can distinguish a manageable deviation trend from a systemic quality-culture failure in real time.
If you do not have a CMC board member, you need a CTO who can translate operational risk into language directors and investors understand — and create an unfiltered information channel so the board learns about manufacturing risk before it becomes a CRL. The most undervalued CTO capability in biopharma.
The one question every board should ask: Does your CTO have the authority that matches your dominant mandate?
Shaped by the collective careers of sixteen CTOs who have led CMC, Manufacturing and Quality at world-leading Fortune 100, mid-cap, and startup biotech — more than 120 commercial product launches between them. This is not one operator's opinion; it is the institutional memory of the people who have actually shipped medicine, organized into a single governance model.
The complete governance matrix, the Board Calibration Tool, and the operational KPI sets. Free. No sales call, no demo, no follow-up sequence.
Get the framework →Front-end demo. On the live site this delivers the PDF instantly.
If you would like to discuss how this applies to your board, your CTO mandate, or your next technical leadership hire, we welcome the conversation.
